Scenarios of a post-antibiotic society are dire and include massive, highly preventable loss of life, widening socio-economic disparities, and significant economic shortfalls. Estimates of the potential economic impact of antimicrobial resistance (AMR) could be as large as a global annual GDP shortfall of nearly $3.4 trillion by 2030 and $7 trillion by 2050.[i] Currently, 700,000 people die every year due to drug-resistant infections globally.[ii]
Amid the backdrop of the 72nd United Nations General Assembly (UNGA), USP introduced its Quality Institute – a center that will conduct much-needed research to foster evidence-based policy decisions that can help increase the availability of quality-assured medicines worldwide.